Compare VBIX & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VBIX | TVRD |
|---|---|---|
| Founded | N/A | 2017 |
| Country | Israel | United States |
| Employees | 21 | 12 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.1M | 34.6M |
| IPO Year | N/A | N/A |
| Metric | VBIX | TVRD |
|---|---|---|
| Price | $3.60 | $3.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.50 |
| AVG Volume (30 Days) | 25.6K | ★ 37.5K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.96 | $2.75 |
| 52 Week High | $6.31 | $43.65 |
| Indicator | VBIX | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 88.05 | 48.00 |
| Support Level | $2.54 | $2.83 |
| Resistance Level | $3.70 | $4.32 |
| Average True Range (ATR) | 0.22 | 0.31 |
| MACD | 0.12 | -0.04 |
| Stochastic Oscillator | 98.39 | 16.31 |
ViewBix Inc operates in the field of digital advertising. The company operates in single segment, the search segment that develops various technological software solutions, which perform automation, optimization, and monetization of internet campaigns, to obtain and route internet user traffic to its customers.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.